Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

NRIX

+ Watchlist+ Portfolio

Nurix Therapeutics, Inc.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$14.24
52-Week Range
$12.61 – $28.23
Market Cap
$1.54B
P/E (TTM)
5.85
EPS (TTM)
2.41
Dividend Yield
0.00%
Advanced Metrics
Price/Book
1.59
PEG Ratio
—
Return on Equity
43.99%
Return on Assets
21.08%
Gross Margin
52.41%
Operating Margin
41.27%
Profit Margin
42.01%
Current Ratio
8.44
Debt/Equity
0.07
Total Debt
$65.33M
Free Cash Flow
$233.34M
Revenue Growth
8426.30%
Earnings Growth
—
Enterprise Value
$557.50M

Market Snapshot

About

Nurix Therapeutics, Inc. is a clinical-stage biotechnology company developing targeted protein degradation therapies for cancer and immune disorders. The company uses its proprietary DELigase platform to discover small molecules that harness the ubiquitin-proteasome system to degrade disease-causing proteins. Nurix has multiple drug candidates in clinical development targeting difficult-to-treat cancers and inflammatory diseases.